FDA approves lifesaving test for tuberculosis

August 22, 2013, Rutgers University
FDA approves lifesaving test for tuberculosis
David Alland calls his rapid TB test a "laboratory in a cartridge." Credit: John Emerson

A health scourge once considered to be largely contained in the United States has made an alarming resurgence in parts of the country. Recent tuberculosis outbreaks – including an episode in South Carolina that infected 53 children – have brought renewed attention to the need to remain vigilant against that potentially deadly disease.

To combat the both here and especially around the world, a Rutgers New Jersey Medical School has developed a that can rapidly diagnose and classify the disease in a fraction of the time needed by previous technology. Experts agree that a speedy diagnosis can both limit infections and save lives.

Rutgers Today talked to David Alland, director of the Center for Emerging Pathogens at Rutgers New Jersey Medical School, about his many years of work developing the test – called the Xpert MTB/RIF Assay – endorsed by the World Health Organization in 2010. The Food and Drug Administration approved the new in late July for use in the U.S.

Rutgers Today: How does the newly approved test advance the diagnosis of TB?

Alland: The existing technology is a labor-intensive system that involves examining separate samples of saliva on a series of slides under a microscope, and results may not be available for a week or more. Using the system we developed and the FDA just approved results come back within two hours. In addition to being quick, our system detects TB more reliably, while also determining whether the strain of TB found in a patient is drug resistant, something the could not do.

Rutgers Today: Why is it so important to know whether a case of TB is drug resistant?

Alland: If you have multi-drug resistant TB and you don't get the appropriate treatment for it, your chances of dying are about 50 percent, and of course you remain contagious. Fortunately, there are now some drugs that appear to work pretty well for strains of tuberculosis that might have been considered totally drug resistant just a few years ago. But those treatments are both toxic and lengthy, and it takes a lot of courage for a patient to endure them. They only should be used in who clearly need them, so getting an accurate diagnosis is critical.

Rutgers Today: Now that the FDA has approved its use in the United States, how will the test change treatment for patients suspected of having TB?

Alland: Up until now, when TB has been suspected, patients have needed to be kept in hospital isolation wards for the several days that it takes for microscope testing to be completed. Not only is it extremely expensive to keep a patient hospitalized for that length of time, but patients in isolation rooms tend to be treated less attentively, and their conditions can easily deteriorate there. With a quick diagnosis, in theory we can rule out TB for some patients in the emergency room before we even have to put them in isolation, and patients who are infected can start receiving appropriate treatment immediately. That helps both the patient and the health care system's bottom line.

Rutgers Today: The test is already in use in much of the rest of the world. Has it proven itself?

Alland: Its ability to save lives has been documented. The World Health Organization (WHO) reports that for every 100 patients with HIV who are diagnosed with my test there is one more life saved compared with how TB was diagnosed before. People whose immune systems are compromised by HIV are especially vulnerable if they contract TB. With more than one million new cases of people with combined HIV and tuberculosis reported each year, if more people can be tested and then treated, the numbers of lives saved can be huge.

Rutgers Today: What's next?

Alland: We are developing a new generation of the test that not only detects multiple drug resistance in TB, but will be able to pinpoint which specific drugs are resisted and which are not. Also, some of the techniques we've used for TB are now being used to develop a test for fungal sepsis, which is a major problem for debilitated hospitalized patients, including transplant patients and cancer patients. That test is looking very promising. We also have a panel of very sensitive tests for bioterrorism agents such as anthrax and tularemia that could be ready to roll out if this country is ever attacked with those agents.

Explore further: New hope for improved TB treatments

Related Stories

New hope for improved TB treatments

August 9, 2013
Researchers at the University of Southampton have identified new markers of tuberculosis (TB) that may help in the development of new diagnostic tests and treatments.

Rapid test allows for earlier diagnosis of tuberculosis in children

July 25, 2013
A new test for diagnosing tuberculosis (TB) in children detects roughly two-thirds of cases identified by the current culture test, but in a fraction of the time, according to the results of a study in South Africa supported ...

Still long delays in diagnosing TB and HIV

May 31, 2013
It still takes a long time for TB and HIV patients in Uganda to be properly diagnosed. As a result, many patients are infectious without knowing it themselves. These diagnostic delays, and also adherence to therapy, can be ...

Potential new drug for tuberculosis

August 5, 2013
A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB).

A better tool to diagnose tuberculosis

April 9, 2012
Up to 30% of the world's population is infected with Tuberculosis (TB), but in many areas of the world, TB diagnosis still relies on insensitive, poorly standardized, and time-consuming methods. A new diagnostic tool, endorsed ...

New test for tuberculosis could improve treatment, prevent deaths in Southern Africa

November 20, 2012
A new rapid test for tuberculosis (TB) could substantially and cost-effectively reduce TB deaths and improve treatment in southern Africa—a region where both HIV and tuberculosis are common—according to a new study by ...

Recommended for you

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Aug 22, 2013
I like the GenXpert. That being said it has some major drawbacks. First, it does NOT detect MDR tuberculosis. MDR tuberculosis is defined as resistance to Rifampin and INH. This test only detects Rif resistance. Most of the time if they are resistant to one they are resistant to the other, but not all of the time. Second, this test completely destroys your sample. Further testing cannot be done if the sample is positive. You have to go back and get the patient and get another sample, which is not as easy as you might think. There are other tests available that offer actual MDR and even XDR results in about 5 hours that do not kill off the sample. Most of these are in-house tests, but a commercially available kit is made by Hain Lifescience out of Germany. These are not FDA approved, but most tests made for M. tb are not FDA approved. This mostly has to do with the cost of FDA approval and our extremely low incidence. You cannot make your money back and its not needed.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.